MedTrace Logo

Efficacy of ProgenaMatrix™ in the Management of DFUs

NCT06292026 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-03-04

No results posted yet for this study

Summary

This multicenter study will collect data to determine closure time for diabetic ulcers when following protocol parameters and treatment with ProgenaMatrix™.

Conditions

  • Diabetic Foot Ulcer

Interventions

DEVICE

ProgenaMatrix Keratin graft

place ProgenaMatrix graft on the wound

OTHER

standard of care

apply non adherent dressing

Sponsors & Collaborators

  • ProgenaCare Global, LLC

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-14
Primary Completion
2026-03-31
Completion
2026-09-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06292026 on ClinicalTrials.gov